Clinical Trial Update: Comparison of Multigam IV (5% vs. 10%) in Patients With an Immunodeficiency Secondary to a Hematological Disorder

View source ↗

Summary

A completed clinical trial comparing 5% vs 10% Multigam IV in patients with immunodeficiency due to a hematologic disorder; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Diseases
• Immunodeficiency

Drugs mentioned

• Multigam IV (intravenous immunoglobulin (IGIV))

Snippet

Sponsor: Universitaire Ziekenhuizen KU Leuven | Conditions: Hematologic Diseases, Secondary Immune Deficiency | Status: COMPLETED | Results posted: 2019-11-15